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Abstract
Background: Radiotracer imaging of the presynaptic nigrostriatal dopaminergic system is used to assess disease
progression in Parkinson’s disease (PD) and may provide a useful adjunct to clinical assessment during therapeutic trials of
potential neuroprotective agents. Several clinical trials comparing dopamine agonists to L-DOPA or early vs. late L-DOPA
have revealed differences between clinical assessment and imaging of the presynaptic dopaminergic system, hence
questioning the comparability of these measures as neuroprotection outcome variables. Thus, results of these studies may
have been affected by factors other than the primary biological process investigated.
Methodology/Principal Findings: We tested the possibility that L-DOPA might interfere with DAT binding. Post-mortem
DAT binding was conducted in normal and MPTP-treated macaque monkeys that were administered L-DOPA, acutely or
chronically. In parallel, DAT SPECT was conducted in MPTP-treated animals that were administered chronic L-DOPA.
[99mTc]TRODAT-1 SPECT binding was similarly reduced in all MPTP monkeys regardless of L-DOPA treatment. L-DOPA had
no significant effect on post-mortem DAT binding either in saline or in MPTP-lesioned animals.
Conclusions/Significance: These data indicate that L-DOPA does not induce modifications of DAT expression detectable by
SPECT of by DAT binding autoradiography, suggesting that differences between clinical assessment and radiotracer
imaging in clinical trials may not be specifically related to L-DOPA treatment.
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Introduction
Radiotracer imaging of the presynaptic nigrostriatal dopami-
nergic system is a useful tool to assess the rate of disease
progression in Parkinson’s disease (PD). In longitudinal studies, F-
DOPA PET and dopamine transporter (DAT) SPECT show a 4%
to 13% yearly reduction in baseline putamen uptake compared
with 0 to 2.5% in healthy controls [1,2,3,4,5,6]. Such techniques
may therefore provide a useful adjunct to clinical assessment in
monitoring disease progression in therapeutic trials of potential
disease modifying therapies.
However, three clinical trials comparing dopamine agonists to L-
DOPA (CALM-PD and REAL-PET) or early vs. late L-DOPA
(ELLDOPA) have revealed discrepancies between clinical assess-
ment and radiotracer-based imaging of the dopaminergic system as
assessed by b-CIT or F-DOPA PET [7,8,9], thus questioning the
adequacy of these measures as outcome variables. Such a mismatch
not only limits the interpretation of these studies but also hinders
future developmentof disease modifyingtherapies since biomarkers
and biological endpoints are mandatory to demonstrate a putative
neuroprotective effect of a drug. The results of these clinical trials
and the divergence between clinical and imaging endpoints have
been the subject of an intense debate [10,11,12,13,14]. The reasons
for such differences currently remain unknown and several
hypotheses have been proposed, including L-DOPA-induced
modification of DAT expression, interaction with radiotracers or
accelerated loss of nigrostriatal terminals.
Since the results of these imaging studies may have been
affected by factors other than the primary biological process under
study, we tested the hypothesis that chronic L-DOPA treatment
might interfere with DAT expression or with the imaging
procedure. To determine whether L-DOPA may interfere with
radioligand binding, we performed in vivo DAT SPECT in MPTP-
treated macaque monkeys that were chronically treated with L-
DOPA. We also assessed a potential effect of L-DOPA on DAT
expression using post-mortem DAT binding in a cohort of normal
and MPTP-treated macaque monkeys that were both adminis-
tered L-DOPA, acutely or chronically.
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Animals
Experiments were conducted on fifty-three female rhesus
monkeys (Macaca mulatta, Xierxin, Beijing, PR of China; mean
age =561 years; mean weight =5.360.8 kg). Animals were
housed in individual primate cages under controlled conditions of
humidity (5065%), temperature (2461uC) and light (12 h light/
12 h dark cycles, time lights on 8:00 am), food and water were
available ad libitum and animal care was supervised daily by
veterinarians skilled in the healthcare and maintenance of non-
human primates. Experiments were carried out in accordance
with European Communities Council Directive of 24 November
1986 (86/609/EEC) for care of laboratory animals in an
AAALAC-accredited facility following acceptance of study design
by the Institute of Lab Animal Science IACUC (Chinese Academy
of Medical Sciences, Beijing, China). Experiments followed
previously published procedures [15,16,17,18]. Even though
animals were housed individually, the disposition of cages allowed
each animal to have visual contacts and interact with monkeys
housed in the adjacent cages. Stimulations for play are provided
including rubber toys and mirrors that the monkeys use to view
themselves and to get a greater look around the room. A radio is
played daily from 8.00am–10.00am and 3.00pm–5.00pm to
provide stimulation.
Experimental protocol
Animals were randomly assigned to a particular treatment
group. Six animals were kept as untreated controls (control group),
six monkeys received a single dose of 20 mg/kg L-DOPA p.o
(control acute L-DOPA), six monkeys received 20 mg/kg twice
daily for three months (control chronic L-Dopa). The remaining
23 animals were treated daily (9:00 am) with MPTP hydrochloride
(0.2 mg/kg, i.v., Sigma, St Louis, MO) dissolved in saline
according to a previously described protocol [19,20]. Monkeys
were injected in the femoral vein under gentle restraint. Following
stabilization of the MPTP-induced syndrome, animals received
either saline (MPTP), either a single dose of 20 mg/kg L-DOPA
(MPTP acute L-DOPA) or twice daily for three months (MPTP
chronic L-DOPA). TRODAT SPECT was performed in twelve
additional monkeys: four untreated controls, four MPTP and four
MPTP chronically treated with L-DOPA according to exact same
methods and timeline. The experimental flowchart is described on
Figure 1. All animals were killed by sodium pentobarbital
overdose (150 mg/kg, i.v.) 1 hr after the last dose of vehicle or L-
DOPA, and the brains were removed quickly after death. Each
brain was bisected along the midline and the two hemispheres
were immediately frozen by immersion in isopentane (245uC) and
then stored at 280uC. Tissue was sectioned coronaly at 20 mmi n
a cryostat at 217uC, thaw-mounted onto gelatine-coated slides,
dried on a slide warmer and stored at 280uC.
Behavioural assessment
Animal behaviour was assessed in their home cages. All
observers were blinded with regard to the experimental protocol.
During each session, two blinded examiners evaluated the level of
motor performance of each animal, by coaxing them to perform
various tasks by offering appetizing fruits. Animals received
supplemental feeding from day 7 onwards to maintain their body
weight as constant as possible. The degree of parkinsonism was
assessed daily (9 a.m.) for 30 min using a validated parkinsonian
macaque clinical scale [15,20,21] which rates the following
symptoms of parkinsonian disability: tremor, variations in the
general level of activity, body posture (flexion of spine),
vocalization, freezing and frequency of arm movements (reaching
for food for each upper limb) and rigidity (for each upper limb).
The minimal disability score was 0 and the maximum score was 25
[21]. The severity of dyskinesia was rated using the Dyskinesia
Disability Scale [22,23,24]: 0, dyskinesia absent; 1, mild, fleeting,
and rare dyskinetic postures and movements; 2, moderate, more
prominent abnormal movements, but not interfering significantly
with normal behaviour; 3, marked, frequent and, at times,
continuous dyskinesia intruding on the normal repertoire of
activity; or, 4, severe, virtually continuous dyskinetic activity,
disabling to the animal and replacing normal behaviour. Daily
behavioural assessments were performed before and after L-Dopa
administration. Median rating scores and SEM were calculated
daily for each group.
[
99mTc]TRODAT-1 SPECT
Anaesthesia was induced by ketamine (i.m., 15 mg/kg,
Imalgene, Centravet, France) in animals having received their
last dose of vehicle or L-DOPA the day before scanning. A
polycarbonated custom-made stereotaxic device (Blueprint by
Primate Research Center, University of Washington, Seattle,
USA) maintained the monkey’s head in the SPECT camera to
allow reproducible positioning of the animal. Reproducibility of
the tomographic technique had been ensured by repeating the
assessment twice in one normal and one fully parkinsonian animal
and on the basis of our previous experience with another SPECT
system [25]. Single-vial kit (National Laboratory of Nuclear
Medicine, Suzhou, China) containing 100 mg of TRODAT-1,
20 mg of stannous chloride anhydrous, 10 mg of sodium gluco-
heptonate was added with 3.7 GBq (0.5 to 1.0 ml) of [
99mTc]
pertechnetate. The reaction mixture was heated for 30 minutes at
100uC and then cooled to room temperature. The radiochemical
purity was kept at .90% as evaluated by thin layer chromatog-
raphy. To diminish non-specific binding of pertechnetate to the
choroid plexus (i.e. to increase the signal to noise ratio as per
manufacturer recommendation) 10 mg/kg of KClO4 was admin-
istered by bolus injection 30 min before 10 mCi [
99mTc]-
TRODAT-1 was injected in the femoral vein. SPECT was
performed 3 hours after the injection of radiopharmaceuticals.
Data were acquired at 20 s per view, using 64 views and a
1286128 matrix, and were reconstructed using Butterworth
filtered back projection with a slice thickness of 3.9 mm. All
images were obtained on the same double-head camera (e.cam
duet
Signature Series multipurpose gamma camera Siemens, USA).
SPECT was performed with low-energy-high-resolution parallel
hole Fan-beam collimators at 3.2 enlargement (collimators
specially designed for brain scanning). Parameters were as follows:
energy window: 140 keV, matrix: 128_128, 6u/projection, 40 s
per projection and 180 projection angles per detector over 360u.
After back-projection, a Butterworth low-pass filter with an order
of 8.0 and a cut-off of 0.2 was applied. Attenuation correction was
accomplished using Chang’s first order correction method.
The values are the mean of one acquisition in each individual.
In normal animals, standardized oval regions of interest (ROI) for
right and left striata (ST) and for the cerebellum (CB) have been
determined on transverse slice according to a median sagittal line
and a perpendicular line passing through the temporal lobes as
previously described [26]. These geometrical ROIs had a volume
of 0.3 ml for striatum according to macaque brain anatomical
data [27]. In MPTP-treated animals we used the same size of
ROIs without considering potential striatal atrophy consecutive to
MPTP intoxication. The striatal specific uptake of [
99mTc]-
TRODAT-1 was calculated (Mean 6 S.E.M.) according to the
ratio of (ST-CB)/CB.
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DAT binding using [
125I]-(E)-N-(3-iodoprop-2-enyl)-2b-carbox-
ymethyl-3b-(49-methylphenyl)-nortropane (PE2I;Chelatec, France)
was measured on fresh-frozen cryostat-cut 20 mm thick slide-
mounted coronal sections as previously described [15,20]. Sections
incubated in the presence of 100 mM cocaine (Sigma) were used to
define nonspecific binding [15,20]. After substraction of back-
ground for non-specific staining, densitometric analysis of autora-
diographs was performed using an image analysis system (Densirag
V2.0, Explora Nova, La Rochelle, France). Two rostrocaudal levels
wereanalyzedinaccordancewiththe functionalorganizationofthe
striatum: a rostral (associative) level including the caudate, putamen
and nucleus accumbens (anterior commissure +2 mm); and a
caudal (motoric) level including the body of the caudate, the
putamen and both parts of the globus pallidus (i.e. pars externalis
and pars internalis) (anterior commissure 24 mm). Where
appropriate, both caudate and putamen were divided into
dorsolateral, dorsomedial, ventrolateral and ventromedial quad-
rants for analysis. Two sections per animal and per striatal level
were analysed by an examiner blind with regard to the
experimental condition. Optical densities (mean 6 SEM) were
averaged for each region in each animal.
Statistical analysis
SPECT data were analyzed using one-way ANOVA followed
by Bonferroni post-hoc test. DAT binding data were analysed using
two-way ANOVA followed by post-hoc t-tests corrected for multiple
comparisons by the method of Bonferroni [28]. Comparison of
DAT binding intensity among striatal subregions in MPTP-treated
monkeys was performed using one-way ANOVA followed by
Bonferroni post-hoc test. These analyses were completed using
STATA program (Intercooled Stata 6.0, Stata Corporation,
College Station, TX). A probability level of 5% (p,0.05) was
considered significant.
Results
Evolution of symptoms and behavioural assessment
MPTP-treated animals displayed the classic progression of
symptoms previously shown with this intoxication regimen
[17,20]. Monkeys became increasingly bradykinetic, adopted a
stooped posture, with increased rigidity of the limbs and decreased
vocalization. Movement accuracy progressively deteriorated and
there were occasional episodes of freezing as well as postural
tremor. Stable parkinsonism was obtained after 1960.5 MPTP
injections (parkinsonian score =9.360.34). All MPTP groups
displayed a similar parkinsonian score (MPTP: 8.560.5, MPTP
acute L-Dopa: 9.560.5, MPTP chronic L-Dopa (dyskinetic):
9.3360.4, MPTP chronic L-Dopa (non dyskinetic): 9.8360.87).
Parkinonian scores of all MPTP groups were significantly different
from controls (F6,35=88.12, p,0.0001) and identical between
them. Animals who developed L-Dopa induced dyskinesia
following chronic L-Dopa treatment had a dyskinetic score of
2.3360.21.
In vivo DAT imaging
In vivo [
99mTc]-TRODAT-1 binding using SPECT was
measured in in control, MPTP and MPTP chronically treated
with L-DOPA (Fig. 2). ANOVA analysis demonstrated a
significant effect of MPTP (F(2,9)=50.93, p,0.0001). Post-hoc
analysis further revealed that scans performed in MPTP and
MPTP with chronic L-DOPA treatment showed a significant
decrease in [
99mTc]-TRODAT-1 binding compared with control
animals (Fig. 2). There was no difference between MPTP and
MPTP + chronic L-DOPA conditions.
Ex vivo DAT binding autoradiography
DAT binding autoradiography using [
125I]-PE2I was performed
at two rostrocaudal levels of the striatum. At the rostral
(associative) level, there was a significant effect of MPTP in all
striatal subregions investigated both in the caudate nucleus
(dorsomedial: F1,36=1344.12, p,0.0001, dorsolateral: F1,36=
1063.6, p,0.0001, ventromedial: F1,36=788.01, p,0.0001,
ventrolateral: F1,36=740.23, p,0.0001) and in the putamen
(dorsomedial: F1,36=916.92, p,0.0001, dorsolateral: F1,36=
1146.09, p,0.0001, ventromedial: F1,36=335.47, p,0.0001,
ventrolateral: F1,36=466.53, p,0.0001). (Fig. S1). At the caudal
(motoric) level, DAT binding was also drastically reduced in all
MPTP groups both in the caudate (F1,34=461.23, p,0.0001) and
Figure 1. Experimental flowchart illustrating study design, treatments and group assignments.
doi:10.1371/journal.pone.0014053.g001
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eral: F1,34=985.22, p,0.0001, ventromedial: F1,34=576.71,
p,0.0001, ventrolateral: F1,34=886.54, p,0.0001) (Fig. 3). In
MPTP-treated monkeys, DAT binding was found to be differen-
tially affected among striatal subregions. At the rostral level, there
was a significant regional effect of MPTP both in the caudate
(F1,19=8.214, p,0.01) and in the putamen (F1,19=49.80,
p,0.0001, Fig. S1). Post hoc analysis revealed a greater loss of
DAT binding in the dorsolateral and dorsomedial caudate
compared with the ventrolateral subregion (p,0.05). In the
putamen, the loss of DAT binding was more pronounced in the
dorsolateral and dorsomedial subregions compared with the
ventromedial (p,0.001) and ventrolateral subregions (p,0.001).
Such differential vulnerability was also found in the putamen at
the caudal level (F1,19=8.601, p,0.01, Fig.3). Post-hoc analysis
revealed a greater effect of MPTP in the dorsolateral compared
with dorsomedial (p,0.05) and ventromedial subregions (p,0.05).
However, there was no significant effect of acute or chronic L-
Dopa treatment and no significant interaction between MPTP and
L-DOPA on DAT binding in any experimental group and striatal
subregions.
Discussion
The unexpected divergence between clinical and imaging
endpoints reported in several clinical trials in PD is not only
puzzling but also an obstacle for the development of future
therapeutic trials. Even though the validity of DAT imaging as a
surrogate marker for clinical trial has been legitimately questioned
[29], the reproduction of this mismatch in three independent
investigations and using different markers (F-DOPA and b-CIT)
suggests that factors other than the imaging technique may have
influenced the outcomes. Among such possibilities, pharmacolog-
ical interactions between radiotracers and L-DOPA and/or L-
DOPA-induced reduction of DAT expression have been suggested
[10,30]. In addition, compensatory mechanisms involving changes
in binding sites or enzyme activities may also be involved [31].
Indeed, partial lesions of the nigrostriatal projection are associated
with a reduction of the density of high affinity DAT binding sites
together with a large increase of the density of low affinity binding
sites and a further reduction of their affinity [32]. These data
suggest that the mechanisms underlying altered DAT function
may have an impact when using DAT radioligands.
In the present study, we sought to determine whether acute or
chronic L-DOPA treatment at therapeutically relevant doses may
interfere with the radiotracer or induce modifications of DAT
expression that could be detected either by in vivo by SPECT or ex
vivo using DAT binding autoradiography.
[
99mTc]-TRODAT-1 SPECT performed 24 h after the last L-
DOPA administration was significantly reduced following MPTP
and L-DOPA treatment did not induce an additional reduction of
TRODAT-1 binding, suggesting that L-DOPA does not interfere
with TRODAT-1 binding to the DAT. As we and others have
previously shown, DAT reduction estimated in vivo by SPECT is
lower compared with ex vivo quantification of dopaminergic cell
bodies or terminals [33,34]. Even though a previous study in rats
showed a significant decrease of TRODAT SPECT binding in
rats receiving 125 or 150 mg/kg L-DOPA [35], our SPECT
results using therapeutically relevant doses are in agreement with
previous work showing that [
123I]beta-CIT or [
123I]FP-CIT
binding is not affected by L-DOPA treatment in PD patients
[36,37]. Therefore, factors specifically related to L-DOPA
treatment such as dose, duration of treatment and wash-out
period do not appear to have a strong influence on DAT imaging.
However, in some of the clinical trials the greater reduction of
DAT binding in patients receiving L-Dopa was observed
compared with patients receiving various regimens of dopamine
agonists (ropinirole or pramipexole) [7,9]. Therefore, a specific
effect of dopamine agonists on DAT binding may also be involved
and cannot be inferred from the present study.
Indeed, DAT availability can be pharmacologically regulated
since several drugs including antidepressants, opioı ¨ds and CNS
stimulants may influence DAT imaging (for review, see Booij and
Kemp, 2008). Genetic regulation is also involved as polymor-
phisms in the 39 untranslated region of the DAT gene are
associated with higher striatal DAT availability [38,39]. DAT
SPECT can also be influenced by a number of other factors
including smoking [40], body mass index [41], or anxiety and
depression [42].
In order to investigate DAT density with a higher sensitivity, we
performed ex-vivo DAT binding autoradiography at two rostro-
caudal levels of the caudate and putamen using [
125I]-PE2I. While
DAT binding was dramatically reduced in all MPTP groups, there
was no significant difference between saline and L-DOPA-treated
MPTP animals (acute or chronic) in any of the striatal levels and
subregions investigated. However, out of 13 striatal subregions
investigated, there was a small non-significant decrease in MPTP
monkeys treated with L-DOPA in 4 putaminal subregions at the
rostral, i.e. associative, level (Fig S1). This trend was not found in
the rostral associative caudate nor in the caudal motoric caudate
or putamen. While these observations are consistent with a
previous study showing a 5% decrease in size of the DAT terminal
tree in normal rats treated chronically with L-DOPA [43], acute
or chronic treatment with L-DOPA did not influence DAT
binding in normal animals in our study. In addition, the
occurrence of L-DOPA-induced dyskinesia was not associated
with differences in DAT binding in agreement with previous
results [44]. Previous studies investigating the effects of dopamine
agonists or L-DOPA on DAT binding in normal or dopamine-
depleted animals have shown contrasting results [45]. Interesting-
ly, all ex-vivo binding studies showing a significant effect of L-
DOPA on dopamine uptake sites in the striatum were performed
with [
3H]-mazindol [46,47,48]. Conversely, [
3H]-GBR-12935,
[
3H]-WIN-35,428, [
3H]-cocaine, [
123I]-b-CIT or [
125I]-PE2I did
Figure 2. In vivo assessment of DAT density using [
99mTc]TRO-
DAT-1 SPECT in control, MPTP and MPTP-monkeys treated
chronically with L-Dopa. ** indicates significant difference com-
pared with control group (p,0.001 using Bonferonni test following
one-way ANOVA). Representative SPECT images are shown for each
group.
doi:10.1371/journal.pone.0014053.g002
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One noticeable difference between these DAT ligands is the very
high affinity of mazindol for the norepinephrine transporter
(Ki=3 nM) [53]. Conversely, PE2I has a very low affinity for the
norepinephrine transporter (.1000 nM) [54,55]. In addition, the
drugs used to define non-specific binding and duration of film
exposure may have played a role in the apparent variable effects of
L-DOPA on DAT density when measured ex vivo.
Several important differences between clinical trials and
experimental studies should be emphasized: the degree of
dopaminergic lesion in MPTP-Treated monkeys in this study is
greater than that of PD patients enrolled in clinical trials. It is thus
possible that the extent of the lesion in our study may have
prevented to observe an effect that may exist in patients. Indeed,
adaptative mechanisms including modified DAT binding proper-
ties have been shown following partial nigrostriatal lesions [32].
Figure 3. DAT binding autoradiography in the posterior striatum (AC 24 mm). A. Representative DAT binding autoradiogram from a
control animal illustrating the position of striatal subregions. B. Representative autoradiogram from a MPTP-treated monkey. Cd: caudate nucleus,
Put: putamen DL: dorsolateral, DM: dorsomedial, VL: ventrolateral, VM: ventromedial. ** indicates significant difference compared with corresponding
control group (p,0.001 using Bonferonni test following two-way ANOVA).
doi:10.1371/journal.pone.0014053.g003
L-DOPA and DAT
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animals even though the present study is unprecedented in that
respect. They thus have a limited power to detect subtle
differences that can be observed in clinical studies involving large
cohorts of patients (i.e. .40–60 patients). A power analysis (power
80%, alpha =0.05) reveals that at the caudal motoric level of the
striatum, between 44 and 145 animals would have been needed to
detect a difference between MPTP and MPTP-L-DOPA animals
in the caudate nucleus (i.e. the less motor involved part of the
caudal striatum). However, in the four putaminal quadrants, (i.e.
in the motor part of the striatum), between 340 and 6600 animals
would have been needed to obtain a significant difference.
Nevertheless, our results suggest that regulation of DAT
expression is not influenced by an acute or chronic treatment
with L-DOPA both in normal and MPTP-lesioned monkeys at
therapeutically relevant doses. Even though the 3-month L-DOPA
treatment performed in the present study is shorter than the
duration of treatment in the human disease, it is sufficient for the
occurrence of plastic changes, transcriptional and post-transcrip-
tional adaptations as shown with LID and by far longer than the
vast majority of previous preclinical experiments. One should
however acknowledge that the MPTP monkey model of PD,
although it recapitulates many features of the human disease [56],
is not the disease. The present results suggest that L-DOPA itself is
unlikely to be solely responsible for the decreased DAT binding
observed in PD patients in clinical trials. Further studies should
investigate the involvement of other factors, one being the specific
regulation of DAT expression in diseased neurons and/or
terminals.
Supporting Information
Figure S1 DAT binding autoradiography in the rostral striatum
(AC+2 mm). A. Representative DAT binding autoradiogram from
a control animal illustrating the position of striatal subregions. B.
Representative autoradiogram from a MPTP-treated monkey. Cd:
caudate nucleus, Put: putamen DL: dorsolateral, DM: dorsome-
dial, VL: ventrolateral, VM: ventromedial. ** indicates significant
difference compared with corresponding control group (p,0.001
using Bonferonni test following two-way ANOVA).
Found at: doi:10.1371/journal.pone.0014053.s001 (3.52 MB TIF)
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